Cambridge Healthtech Institute’s 10th Annual

Engineering Antibody-Drug Conjugates

Innovations in Next-Generation ADC Design

May 6-7, 2020


A successful ADC requires the combination of the right target, right antibody, right linker and the right payload. Getting it right can create ADCs that have the potential to become a life-saving medicine for many diseases, especially cancer. At CHI's Engineering Antibody-Drug Conjugates, speakers will share their creative strategies, whether in altering the antibody effector moiety, testing new payloads, selecting novel targets, or reinventing conjugation technologies, and discuss their progress to-date.

Preliminary Agenda

KEYNOTE PRESENTATION
Ugly Ducklings: Why Clinical Effective Antibody-Drug Conjugates May Not Look That Pretty (at First)… and How to Spot Them

Greg M. Thurber, PhD, Associate Professor, Chemical Engineering and Biochemical Engineering, University of Michigan

ENGINEERING THE ANTIBODY EFFECTOR MOIETY

Targeted C'Dot-Drug Conjugates for the Treatment of Cancer

Greg Adams, PhD, CSO, Elucida Oncology, Inc.

Engineered Avibodies (Enhanced Diabodies) Precisely Loaded with Novel ADC Payloads that Surpass IgG-ADCs in Cancer Therapy

Peter Hudson, FTSE, PhD, Chief Scientist and CSO, Avipep Pty Ltd.

Probody™ Therapeutics in the Treatment of Cancer

Siew Schleyer, PhD, Director, Oncology Research, CytomX Therapeutics

NEW/SPECIALTY PAYLOADS

NBE-002, An Anthracycline-Based Immune Stimulatory Antibody-Drug Conjugate (iADC) Targeting ROR1 for the Treatment of Triple Negative Breast Cancer

Roger R. Beerli, PhD, CSO, NBE-Therapeutics AG

Development of Novel Payloads for Next-Generation ADCs

Robert Lutz, PhD, CSO, Iksuda

Controlled Masking of Redox Cyclers for Intracellular Activation

Goncalo Bernardes, DPhil, Reader (Associate Professor), Chemical Bioogy, University of Cambridge

ADCs TARGETING THE TUMOR MICROENVIRONMENT

Antibody-Drug Conjugates (ADCs) and Small Molecule Drug Conjugates (SMDCs): A Comparative Analysis

Dario Neri, PhD, Professor, Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zurich)

TM4SF1: An Attractive Vascular and Tumor Cell Target for Antibody-Drug Conjugate Therapy

Shou-Ching Jaminet, PhD, Founder & Head of Research, Angiex, Inc.

IMB-213: A Novel Secretome-Targeted Biologic for the Selective Delivery of Immunomodulatory Payloads to Solid Tumors

Anton Neschadim, PhD, MBA, CEO, ImmunoBiochem Corporation

SITE-SPECIFIC CONJUGATION AND LINKER TECHNOLOGIES

Conjugating Payloads to Native Antibodies without the Need for Any Prior Antibody Engineering in a Single or Two Steps

Philipp Spycher, PhD, CEO, Araris Biotech AG

Achieving High DAR ADCs Using Site Specific Cysteine-Based Conjugation

Amit Kumar, PhD, Scientist, AstraZeneca



* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean


Update History
2019/11/25
Sponsor updated



View By: